



BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015.

Tel. : 0731-2723016 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com

Factory : Plot No. 8, Sector - III, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.) PIN - 454 775

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)

Tel. : 0731-2426700, 2426718 • CIN : L24233MP1985PLC002709

Date: 9th August 2022

To,
The Secretary
Corporate Compliance Department,
**The National Stock Exchange of India
Limited**
Bandra Kurla Complex Mumbai M.H.

To,
The Secretary,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Sub: - Outcome of the Board Meeting held on Tuesday, 9th August 2022 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref- Biofil Chemicals and Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN INE829A01014)

Dear Sir/Madam,

With reference to the above-mentioned subject and as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of the Directors of the Company in their meeting (No. 02/2022-2023) held on today i.e. **Tuesday, 9th August 2022**, has inter alia approved following matters along with other routine businesses:-

1. Approval of the Un-Audited Financial Result and Limited Review Report thereon for the Quarter ended on 30th June, 2022.
2. Approval of Boards' Report on the operation of the Company & its Annexure along with Corporate Governance Report & Management Discussion and Analysis Report for the year ended on 31st March, 2022.
3. Approval of Notice of 37th Annual General Meeting to be held on Friday, 30th September, 2022 through Video Conferencing (VC)/ Other Audio Visual Means (OAVM) to transact the following businesses:-
 - To consider and adopt the Audited Financial Statement of the Company together with the Report of the Board of Directors and the Auditors thereon for the financial year ended March 31, 2022.

- To appoint a Director in place of Mr. Romil Shah (DIN: 00326110) Director of the Company, who retires by rotation in terms of Section 152(6) of the Companies Act, 2013 and being eligible offers himself for re-appointment.
- Re-appointment of M/s Maheshwari & Gupta, Chartered Accountants as statutory auditors of the company and to fix their remuneration.
- Approval of material related party transaction of the company with Cyaño Pharma Private Limited.

The meeting of the Board of Directors commenced at 4.00 p.m. and concluded at 5:35 p.m.

This is for your information and record.

Thanking You,

Yours faithfully

For Biofil Chemicals and Pharmaceuticals Limited


Shikha Khilwani
Company Secretary & Compliance Officer
ACS 43203





BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015.
Tel. : 0731-2723016 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com

Factory : Plot No. 8, Sector - III, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.) PIN - 454 775

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718 • CIN : L24233MP1985PLC002709

Date: 9th August, 2022

To,
The Secretary
Corporate Compliance Department,
The National Stock Exchange of India Limited
Bandra Kurla Complex Mumbai M.H.

To,
The Secretary,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Sub: Submission of Un-Audited Financial Result of the Company for the quarter ended on 30th June, 2022 and Limited Review Report as per Regulation 33(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref- Biofil Chemicals and Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

This is in continuation of our letter dated 2nd August, 2022 regarding information of Board Meeting for consideration and approval of un-audited Financial Results for the quarter ended on 30th June, 2022.

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are pleased to submit the Un-audited Financial Results together with Limited Review Report thereon for the quarter ended 30th June 2022 duly approved by the Board of Directors of the Company at its meeting held today i.e. on Tuesday, 9th August, 2022 at the Registered office of the Company. **Copy of Unaudited Financial Results along with Limited Review Report is enclosed with this letter (searchable PDF mode).**

Further, copy of Un-Audited Financial Statements shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid financial results shall also be uploaded on website of Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the website of the Company at www.biofilgroup.net. The extract of aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper.

You are requested to take on record the above said financial results for your reference and record.

Thanking You,

Yours faithfully

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED


Shikha Khilwani
Company Secretary & Compliance Officer
ACS 43203

Enclosure: Un-audited Financial Results for the quarter ended 30th June, 2022.

Biofil Chemicals & Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com, Website:https://www.biofilgroup.net/ Phone No. 0731-2426718

(Amount in Lakhs except EPS)

Statement of Unaudited Financial Results for the quarter ended 30th June 2022				
Particulars	3 Month Ended 30/06/2022	3 Month Ended 30/06/2021	3 Month Ended 31/03/2022	Previous year ended on March 31 2022
	Un Audited	Un Audited	Audited	Audited
I Revenue from Operation	1230.56	536.87	164.55	2238.23
II Other Income	1.69	2.06	3.01	15.03
III Total Income (I + II)	1232.25	538.94	167.56	2253.26
IV Expenses				
(a) Cost of materials consumed	65.65	55.85	40.30	226.76
(b) Purchases of stock-in-trade	1048.03	47.36	5.27	1360.27
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	41.36	363.63	51.07	359.01
(d) Employee benefits expense	15.09	17.41	23.59	78.67
(e) Finance Cost	1.12	0.97	1.02	4.06
(f) Depreciation and Amortisation Expense	10.69	10.30	11.86	42.75
(g) Other expenses				
1. Manufacturing Expenses	10.80	6.87	14.55	41.48
2. Administrative Expenses	10.31	11.45	14.92	34.85
3. Selling and Distribution Expenses	1.63	1.00	0.66	3.92
Total expenses (IV)	1204.69	514.84	163.25	2151.77
V Profit/ (Loss) before exceptional items and tax (III-IV)	27.56	24.09	4.31	101.49
VI Exceptional Items	0.00	0.00	0.00	0.00
VII Profit/ (Loss) before tax (V - VI)	27.56	24.09	4.31	101.49
VIII Tax expense:				
(1) Current tax	6.94	6.70	2.61	27.10
(2) Deferred tax Credit/(Charge)	0.00	0.00	4.55	4.55
Total Tax expenses	6.94	6.70	7.16	31.65
IX Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-	-	-	-
X Profit/(Loss) for the period from continuing operation (VII-VIII)	20.62	17.39	(2.85)	69.84
XI Profit/(Loss) from dis-continued operation before tax	0.00	0.00	0.00	0.00
XII Tax expenses of discontinued operation	0.00	0.00	0.00	0.00
XIII Profit/(Loss) from dis-continued operation after tax (XI-XII)	0.00	0.00	0.00	0.00
XIV Share of profit (loss) of associates and joint ventures accounted for using equity method				
XV Profit/ (Loss) for the period (X+XIII)	20.62	17.39	(2.85)	69.84
XVI Other Comprehensive Income				
A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	1.35	1.35
(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	(0.34)	(0.34)
B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
(II) Income Tax relating to items that will be reclassified to Profit or Loss			0.00	0.00
XVII Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	20.62	17.39	(1.84)	70.86

Ramgh SSB

XVIII	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38 (319.82)
XIX	Reserves (Excluding Revaluation Reserve)				
XX	Earnings per equity shares (for continuing operation):				
	(1) Basic (Rs)	0.13	0.11	(0.01)	0.44
	(2) Diluted (Rs)	0.13	0.11	(0.01)	0.44
XXI	Earnings Per Equity Share (for discontinued operation)				
	(1) Basic (Rs)	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00
XXII	Earnings Per Equity Share (for continuing & discontinued operation)				
	(1) Basic (Rs)	0.13	0.11	(0.01)	0.44
	(2) Diluted (Rs)	0.13	0.11	(0.01)	0.44

1. The above results for the Quarter ended June 30, 2022 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on 09-08-2022. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

2. This financial results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

3. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.

4. The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

- a. Pharma Division
- b. Chemicals Division

5. The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors

6. The figures for the quarter ended March 31, 2022 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter which were subjected to limited review.

Date : 09.08.2022
Place INDORE

FOR BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)





Biofil Chemicals & Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id: bcplcompliance@gmail.com, Website: https://www.biofilgroup.net/ Phone No. 0731-2426718

Segmentwise Revenue, Results and Capital Employed for quarter ended 30th June-2022

(Amount in Lakhs)

S.No.	Particulars	Quarter Ended			Year Ended
		June 30, 2022	March 31, 2022	June 30, 2021	March 31, 2022
		Un Audited	Audited	Un Audited	Audited
1	Segment Revenue				
	Pharma Division	1,061.18	20.42	468.05	1,900.52
	Chemicals Division	169.38	144.13	68.82	337.71
	Other	1.69	3.01	2.06	15.03
	Gross Revenue	1,232.25	167.56	538.94	2,253.26
2	Segment Results				
	Pharma Division	(2.77)	(11.06)	27.43	98.70
	Chemicals Division	31.44	15.75	(2.89)	4.63
	Other	0.00	0.00	0.00	0.00
	Total Segment Profit Before Tax	28.66	4.69	24.54	103.33
	Interest Income	0.02	0.65	0.53	2.22
	Interest Expenses	1.12	1.03	0.97	4.06
	Other Unallocable Income net of Expenditure				
	Profit Before Tax	27.56	4.31	24.09	101.49
3	Capital Employed				
	Segment Assets (A)				
	Pharma Division	1,905.07	678.10	2,166.20	678.10
	Chemicals Division	1,231.72	1,195.13	1,199.77	1,195.13
	Other		0.00		0.00
	Total (A)	3,136.79	1,873.22	3,365.98	1,873.22
	Segment Liabilities (B)				
	Pharma Division	1,309.71	86.53	1,618.39	86.53
	Chemicals Division	115.75	102.93	110.41	102.93
	Other		0.00		0.00
	Total (B)	1,425.46	189.46	1,728.80	189.46
4	Total Capital Employed (Segment Assets-Segment Liabilities)				
	Pharma Division	595.35	591.56	547.81	591.56
	Chemicals Division	1,115.97	1,092.20	1,089.37	1,092.20
	Other	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	1,711.33	1,683.77	1,637.18	1,683.77

DATE : 09/08/2022
PLACE : INDORE

FOR BIOFIL CHEMICALS & PHARMACEUTICALS
INDORE
RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
DIN: 00028819



LIMITED REVIEW REPORT ON UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2022 OF BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED PURSUANT TO REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS), REGULATION, 2015 (as amended)

To,
The Board of Directors of
Biofil Chemicals and Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited financial results ('the statement') of **Biofil Chemicals and Pharmaceuticals Limited** for the quarter ended 30th June 2022 attached herewith, being submitted by the Company pursuant to Regulation 33 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including relevant circular issued by the SEBI from time to time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review, which has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind As 34) prescribed under Section 133 of Companies Act 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MAHESHWARI & GUPTA**
Chartered Accountants
FRN: 006179C

CA. SUNIL MAHESHWARI
Partner
M. No. 403346



PLACE : INDORE
DATE : 09/08/2022
UDIN : 22403346AOQSRM2614